CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell ...

Demant reported third-quarter earnings with 3% organic sales growth, driven by a 4% increase in Hearing Care, despite a weak global hearing healthcare market caused by macroeconomic uncertainty.

Shares of Lineage Cell Therapeutics Inc. rose after the clinical-stage biotechnology company said it received a research contribution from William Demant Invest A/S under a new collaboration agreement ...

We are transferring coverage of Demant to a new analyst. Demant is a vertically integrated provider of hearing aid devices, developing and manufacturing them and operating a global network of retail ...

Deutsche Bank raised the firm’s price target on Demant (WILYY) to DKK 290 from DKK 285 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

Lineage Cell Therapeutics Inc. has entered into a research collaboration with William Demant Invest A/S to develop Lineage’s auditory neuronal cell transplant Resonance (ANP-1) for hearing loss.

COPENHAGEN, Feb 17 (Reuters) - Danish hearing aid maker William Demant has opened talks to buy French retailer Audika in a deal that would value the company at 168 million euros ($191 million). A ...

Barclays lowered the firm’s price target on Demant (WILYY) to DKK 250 from DKK 268 and keeps an Underweight rating on the shares. Don't Miss our Black Friday Offers: Published first on TheFly – the ...

The European Investment Bank (EIB) is supporting the development of new wireless hearing devices and research into more effective acoustic implants by global leader William Demant Holding A/S through ...

COPENHAGEN, Nov 16 (Reuters) - Danish hearing aid maker William Demant on Monday raised its forecast for sales and operating profits in the second half of this year on the back of stabilising markets.

Morgan Stanley lowered the firm’s price target on Demant (WILYY) to DKK 310 from DKK 325 and keeps an Overweight rating on the shares. Quickly and easily unpack a company's performance with TipRanks' ...